Brief: Prelude Therapeutics Presents Preliminary Results Of Phase 1 Dose-Escalation Study Of PRT2527 As Monotherapy And In Combination With Zanubrutinib
11/12/2024 13:29
Dec 11 (Reuters) - Prelude Therapeutics PRLD.O :
* PRELUDE THERAPEUTICS PRESENTS PRELIMINARY RESULTS OF PHASE
1
DOSE-ESCALATION STUDY OF PRT2527 AS MONOTHERAPY AND IN
COMBINATION WITH ZANUBRUTINIB IN PATIENTS WITH
RELAPSED/REFRACTORY LYMPHOID MALIGNANCIES
* PRELUDE THERAPEUTICS INC: PLANS TO SEEK A PARTNER FOR
FUTURE
DEVELOPMENT OF PRT2527 IN HEMATOLOGIC MALIGNANCIES
Source text: ID:nGNX2ZxGNs
Further company coverage: PRLD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prelude Therapeutics Incorporated
See all newsBrief: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer
U.S. RESEARCH ROUNDUP-Celcuity, Fluence Energy, Salesforce
Prelude Therapeutics Incorporated reports results for the quarter ended June 30 - Earnings Summary
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows
Prelude Therapeutics Incorporated expected to post a loss of 20 cents a share - Earnings Preview